Angiodroid's Angiopulse intra-aortic balloon pump device gains CE mark

Angiodroid announced Wednesday the CE mark for Angiopulse, which is the company's first intra-aortic balloon pump (IABP) device. CEO Sebastiano Zannoli said the approval is "an important step in the context of counterpulsation: now it will be possible to give IABP therapy focusing on pressure regulation." Zannoli noted that "doctors will no longer be concerned with issues related to synchronising the console with heartbeat pulsation", adding that "this now belongs to the past."

According to Angiodroid, the device, which is suitable for all types of patients needing IABP therapy, features a new system for IABP management based on pressure regulation. Angiopulse also offers an "interactive touch screen, remote control via wireless interface, constant monitoring of therapy and [an] interactive user guide," Angiodroid said. The device "is specifically designed for weaning situations" and "contains powerful technological innovations that respond to critical issues raised over the years in the clinical world," the company added.

Did you like this article?